RCUS Arcus Biosciences, Inc.
$24.28 -1.86%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
-1.86%
YTD
+73.10%
P/E
—
P/B
4.67
ROE
-89.5%
Div yield
—
Beta
1.76
Market cap
$3.1B
RSI (14)
37
Next earnings
Oct 26, 2026
Previous session
close of Oct 6, 2026 · EOD, no live order bookOpen
$24.96
Close
$24.28
VWAP (n/a)
—
Day high
$24.84
Day low
$23.96
Volume
825K
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
Is Arcus Biosciences (RCUS) Undervalued As New Casdatifan Data Takes Center Stage?
Yahoo Finance · Oct 6
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
Yahoo Finance · Sep 22
Arcus Biosciences Announces New Employment Inducement Grants
Yahoo Finance · Sep 9
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?
Yahoo Finance · Aug 14
Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript
Yahoo Finance · Aug 13
Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says
Yahoo Finance · Aug 10
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
10-Q Aug 5, 2026 View → 8-K Aug 5, 2026 View → 8-K Jun 12, 2026 View → 10-Q May 5, 2026 View → 8-K May 5, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell RCUS. Try it in the Lab to size a position and see the risk.